Hydroxysteroids

Subscribe to Selected New Research on Hydroxysteroids

10 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: Steroids in which one or more hydroxy groups have been substituted for hydrogen atoms either within the ring skeleton or on any of the side chains.

Bio-Agent Context: Research Results

Polycyclic Compounds: 59

Steroids: 14366

Hydroxysteroids: 10

3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane: 1

Experts

1.	Obayashi, Hiroshi: 1 article (12/2002)
2.	Tagawa, Noriko: 1 article (12/2002)
3.	Kobayashi, Yoshiharu: 1 article (12/2002)
4.	Nakamura, Naoto: 1 article (12/2002)
5.	Nakano, Koji: 1 article (12/2002)
6.	Ohta, Mitsuhiro: 1 article (12/2002)

Related Diseases

1.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 06/01/1997 - "In a previous study, we obtained evidence that A431 cells, derived from an epidermoid carcinoma of the vulva, are enriched in 17-HSD type 2, a membrane-bound isoform reactive with C18 and C19 17 beta-hydroxysteroids and 17-ketosteroids. " Order ALL the reference details at left...
2.	Endometrial Neoplasms (Endometrial Cancer) 07/01/2009 - "Thus, inhibitors of reductive 17beta-HSD isoforms are attractive to block the formation of hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, and hirsutism). " 03/01/2003 - "Thus, inhibitors of 17beta-HSDs are useful tools to elucidate the role of these enzymes in particular biological systems or for a therapeutic purpose, especially to block the formation of active hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, hirsutism, etc). " Order ALL the reference details at left...
3.	Prostatic Neoplasms (Prostate Cancer) 07/01/2009 - "Thus, inhibitors of reductive 17beta-HSD isoforms are attractive to block the formation of hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, and hirsutism). " 03/01/2003 - "Thus, inhibitors of 17beta-HSDs are useful tools to elucidate the role of these enzymes in particular biological systems or for a therapeutic purpose, especially to block the formation of active hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, hirsutism, etc). " Order ALL the reference details at left...
4.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 07/01/2009 - "Thus, inhibitors of reductive 17beta-HSD isoforms are attractive to block the formation of hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, and hirsutism). " 03/01/2003 - "Thus, inhibitors of 17beta-HSDs are useful tools to elucidate the role of these enzymes in particular biological systems or for a therapeutic purpose, especially to block the formation of active hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, hirsutism, etc). " Order ALL the reference details at left...
5.	Hirsutism 07/01/2009 - "Thus, inhibitors of reductive 17beta-HSD isoforms are attractive to block the formation of hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, and hirsutism). " 03/01/2003 - "Thus, inhibitors of 17beta-HSDs are useful tools to elucidate the role of these enzymes in particular biological systems or for a therapeutic purpose, especially to block the formation of active hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgeno-sensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, hirsutism, etc). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	17-Ketosteroids (17 Ketosteroids)
2.	Protein Isoforms (Isoforms)
3.	Steroid 21-Hydroxylase (21 Hydroxylase)
4.	Oxidoreductases
5.	Hydrocortisone (Cortisol)
6.	Enzymes
7.	Dexamethasone (Maxidex)
8.	Cholesterol
9.	3,15,17-trihydroxypregnan-20-one

Best Treatments:
Research Summary Report
on Squamous Cell Carcinoma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 572 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>